跳至主要内容
临床试验/NCT05159544
NCT05159544招募中不适用

A Prospective, Multicenter, Noninterventional Cohort Study of Muti-Omics Models for Pan-Cancer Screening

Singlera Genomics Inc.12 个研究点 分布在 1 个国家目标入组 60,000 人开始时间: 2021年7月6日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
60,000
试验地点
12
主要终点
To evaluate sensitivity,specificity,positive/negative predictive value of the screening model in participants taking routine annual physicals

研究概览

简要总结

The integrative study by Fudan and Singlera for cancer early detection(The FuSion Program ) will evaluate sensitivity,specificity and positive/negative predictive value of the screening model jointly developed by FuDan University and Singlera in a 2-year follow-up corhort including 10,000 persons in routine annual physicals from dozens of hospitals. The multi-omics model for pan-cancer screening will be developed in a 3-year follow-up corhort including 50,000 natural persons in community containing genetic information of tumor families, assessment of epidemiological risk factors, tumor markers, proteomics, genomics and DNA methylation. After optimizing, the ability of this model will be validated in the Taizhou corhort in reality.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
40 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Take physical examinations in our research centers and have no cancer history;
  • "Population Health tracking Survey - simplified version of the questionnaire" must be filled according to the research program and an annual physical examination can be received as follow-up ;
  • Timely feed back the information related to tumor diagnosis in other hospitals to the investigator during the program;
  • Have no birth plan for the last 3 years;
  • Fully understand the study and voluntarily sign the informed consent.

排除标准

  • Have been diagnosed with esophageal cancer, gastric cancer, colorectal cancer, liver cancer, lung cancer, pancreatic cancer, breast cancer (including non-primary, such as recurrence, metastasis or other complications) and other malignant tumors;
  • Received blood transfusion, transplantation and other major operations within 3 months;
  • Participated in other interventional clinical researchs within 3 months;
  • Pregnant or lactating women;
  • Patients with autoimmune diseases, genetic diseases, mental diseases/disabilities and other diseases considered unsuitable for the study by the investigator;
  • Due to poor compliance, the researcher judged that the study could not be completed.

结局指标

主要结局

To evaluate sensitivity,specificity,positive/negative predictive value of the screening model in participants taking routine annual physicals

时间窗: assessed up to 24 months

Sensitivity: the ability of a test to correctly identify patients with a disease. Specificity: the ability of a test to correctly identify people without the disease. Positive predictive value refers to the probability of the person having the disease when the test is positive. Negative predictive value refers to the probability of the person not having the disease when the test is negative.

To develop a multi-omics model for pan-cancer screening integrating the markers of ctDNA mutation, DNA fragmentation and methylation et al.

时间窗: assessed up to 36 months

To construct a multi-dimensional ensembled stacked machine learning approach, employing several different base models on ctDNA mutation, DNA fragmentation and mehylation, to provide an effective model for cancer early detection.

To validate model's efficacy and clinical value in the diagnosis of cancers in Taizhou cohort.

时间窗: assessed up to 12 months

Cancer early detection could increase detection of cancer at early stages, when survival outcomes are better and treatment costs are lower. we will explore whether this model with high specificity could potentially improve long-term health outcomes and reduce cancer treatment costs.

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (12)

Loading locations...

相似试验